Cempra Pharmaceuticals and HiQScreen announced the publication of research revealing the molecular mechanisms that could explain certain unique adverse events associated with the ketolide, telithromycin (Ketek?), which led to its restricted use. The study also showed that Cempra's novel fluoroketolide, solithromycin (CEM-101) is unlikely to generate the adverse events seen with telithromycin. The report was published in the (December) issue of Antimicrobial Agents and Chemotherapy (volume 54: pages 4961 to 4970)...
No comments:
Post a Comment